AVITA Medical Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

22.02.2024 - VALENCIA, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) - AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported ...

Related Keywords

Austria ,United States ,Switzerland ,Australia ,Japan ,Germany ,Australian ,Jim Corbett ,Biomedical Advanced Research ,Development Authority ,Drug Administration ,Human Services ,Us Department Of Health ,Drug Administration Food ,Chief Executive ,Permeaderm Biosynthetic Wound Matrix ,Assistant Secretary ,Conference Call ,Eastern Daylight Time ,Spray On Skin Cells ,Private Securities Litigation Reform Act ,Annual Report ,Chief Financial Officer ,Media Contact ,Jessica Ekeberg Phone ,Avita Medical Chart ,Vita Medical Kurs ,Vita Medical Aktie ,